Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Edwards Lifesciences Corp.

Related EW
Edwards Receives FDA Clearance For Advanced Noninvasive Monitoring System
Edwards Lifesciences' Sapien XT Gains Approval, Competition Rife - Analyst Blog

In a report published Friday, Jefferies & Company reiterated its Buy rating on Edwards Lifesciences Corp. (NYSE: EW), and raised its price target from $115.00 to $125.00.

Jefferies noted, “We published two physician surveys on transcatheter aortic valve replacement (TAVR), one of early adopters and the other of current non-users. Based on the results, which show strong and sustainable procedure growth, we are increasing our forecasts and target. We continue to rate EW shares Buy.”

Edwards Lifesciences Corp. closed on Thursday at $102.88.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (EW)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free